Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 272, Issue 6 35-6, 1997, Pages

  Yoshimoto, Takanobu ^a   Naruse, Mitsuhide ^a   Nishikawa, Megumi ^a   Naruse, Kiyoko ^a   Tanabe, Akiyo ^a   Seki, Toshirou ^a   Imaki, Toshihiro ^a   Demura, Reiko ^a   Aikawa, Eizo ^a   Demura, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Diabetic complications; Insulin resistance; Insulin sensitizing agent; Thiazolidine derivative

Indexed keywords

PIOGLITAZONE; THIAZOLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; MALE; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030825304     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1997.272.6.e989     Document Type: Article

References (37)

1. Ayo, S. H., R. Radnik, J. A. Garoni, D. A. Troyer, and J. I. Kreisberg. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am. J. Physiol. 261 (Renal Fluid Electrolyte Physiol. 30): F571-F577, 1991.
2. Bray, G. A. The Zucker fatty rat: a review. Federation Proc. 36: 148-153, 1977.
3. Brownlee, M., A. Cerami, and H. Vlassara. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318: 1315-1321, 1988.
4. Buchanan, T. A., W. P. Meehan, Y. Y. Jeng, D. Yang, T. M. Chan, J. L. Nadler, S. Scott, R. K. Rude, and W. A. Hsueh. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J. Clin. Invest. 96: 354-360, 1995.
5. Chavers, B. M., R. W. Bilous, E. N. Ellis, M. W. Steffes, and S. M. Mauer. Glomerular lesions and urinary albumin excretion in type 1 diabetes without overt proteinuria. N. Engl. J. Med. 320: 966-970, 1989.
6. Chiang, B. N., L. V. Perlman, and F. H. Epstein. Obesity and hypertension. Circulation 39: 403-421, 1969.
7. Colca, J. R., and D. R. Morton. Antihyperglycemic thiazolidine-diones: ciglitazone and its analogues. In: New Antidiabetic Drugs, edited by C. J. Bailey and P. R. Flatt. London: Smith-Gordon, 1990, p. 255-261.
8. Diani, A. R., S. R. Ledbetter, G. A. Sawada, E. J. Copeland, B. M. Wyse, B. A. Hannah, and T. Peterson. Structural and functional evidence of diabetic nephropathy in the Wistar fatty diabetic rats. In: Frontiers in Diabetes Research, Lessons from Animal Diabetes II, edited by E. Shafrir and A. E. Renold. London: Libbey, 1988, p. 535-541.
9. Dubey, R. K., H. Y. Zhang, S. R. Reddy, M. A. Boegehold, and T. A. Kotchen. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. 265 (Regulatory Integrative Comp. Physiol. 34): R726-R732, 1993.
10. Harrihar, A. P., J. Szollosi, S. Benson, W. C. Hyun, B. G. Feuerstein, and T. W. Kurtz. Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 21: 1020-1023, 1993.
11. Ikeda, H., K. Nishikawa, and T. Matsuo. Feeding responses of Zucker fatty rat to 2-deoxy-D-glucose, norepinephrine, and insulin. Am. J. Physiol. 239 (Endocrinol. Metab. 2): E379-E384, 1980.
12. Ikeda, H., A. Shiono, T. Matsuo, H. Iwatsuka, and Z. Suzuoki. A new genetically obese-hyperglycemic Wistar fatty rat. Diabetes 30: 1045-1050, 1981.
13. Ikeda, H., S. Taketomi, Y. Sugiyama, Y. Shimura, T. Sohda, K. Meguro, and T. Fujita. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim.-Forsch. 40: 156-162, 1990.
14. Iwamoto, Y., T. Kuzuya, A. Matsuda, T. Awata, S. Kumakura, G. Inooka, and I. Shiraishi. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Dictoeies Care 14: 1083-1086, 1991.
15. Kaufman, L. N., M. M. Peterson, and L. M. DeGrange. Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 44: 1105-1109, 1995.
16. Kemnitz, J. W., D. F. Elson, E. B. Roecker, S. T. Baum, R. N. Bergman, and M. D. Meglasson. Pioglitazone increases insulin sensitivity, reduced blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkey. Diabetes 43: 204-211, 1994.
17. Lee, M. K., P. D. Miles, M. Khoursheed, K. M. Gao, A. R. Moossa, and J. M. Olefsky. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43: 1435-1439, 1994.
18. Marks, V., and K. Lloyd. Preservation of blood sample for glucose analysis by glucose oxidase. Clin. Chem. Acta 8: 326, 1963.
19. Mogensen, C. E., and M. J. Andersen. Increased kidney size and glomerular filtration rate in insulin-treatment. Diabetologia 11: 221-224, 1975.
20. Ogihara, T., H. Rakugi, H. Ikegami, H. Mikami, and K. Masuo. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. 8: 316-320, 1995.
21. O'Shaughnessy, I. M., and T. A. Kotchen. Epidemiologic, physiologic, and clinical implications of hypertension and insulin resistance. Curr. Opin. Cardiol. 8: 757-764, 1993.
22. Raiji, L., S. Azar, and W. Keane. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int. 26: 137-143, 1984.
23. Reaven, G. M. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
24. Seyer-Hansen, K. Renal hypertrophy in streptozotocin-diabetic rats. Clin. Sci. Mol. Med. 51: 551-555, 1976.
25. Sowers, J. R., P. R. Standley, J. L. Ram, and S. Jacober. Hyperinsulinemia, insulin resistance, and hyperglycemic: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am. J. Hypertens. 6 Suppl.: 260S-270S, 1993.
26. Sugiyama, Y., Y. Shimura, and H. Ikeda. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim.-Forsch. 40: 436-440, 1990.
27. Sugiyama, Y., S. Taketomi, Y. Shimura, H. Ikeda, and T. Fujita. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneim.-Forsch. 40: 263-267, 1990.
28. Suter, S. L., J. J. Nolan, P. Wallace, B. Gumbiner, and J. M. Olefsky. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15: 193-203, 1992.
29. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes. N. Engl. J. Med. 329: 977-986, 1993.
30. The National High Blood Pressure Education Program Working Group. National high blood pressure education program working report on hypertension in diabetes. Hypertension 23: 145-148, 1994.
31. Yamakawa, T., S. Tanaka, K. Tamura, F. Isoda, K. Ukawa, Y. Yamakura, Y. Takanashi, Y. Kiuchi, S. Umemura, M. Ishii, and H. Sekihara. Wistar fatty rat is obese and spontaneously hypertensive. Hypertension 25: 146-150, 1995.
32. Yamamoto, T., T. Nakamura, N. A. Noble, E. Ruoslahti, and W. A. Border. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA 90: 1814-1818, 1993.
33. Yamatodani, A., and H. Wada. Automated analysis for plasma epinephrine and norepinephrine by liquid chromatography including a sample clean up procedure. Clin. Chem. 27: 1983-1987, 1981.
34. Yoshioka, S., H. Nishino, T. Shiraki, K. Ikeda, H. Koike, A. Okuno, M. Wada, T. Fujiwara, and H. Horikoshi. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42: 75-80, 1993.
35. Zeng, Z. P., M. Naruse, K. Naruse, Y. Kato, Y. F. Shi, H. Demura, and K. Shizume. Antiserum against homologous atrial natriuretic peptide diminishes the natriuretic response during mineralocorticoid escape in rats. Endocrinology 128: 226-230, 1991.
36. Zhang, F., J. R. Sowers, J. L. Ram, P. R. Standley, and J. D. Peuler. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24: 170-175, 1994.
37. Zhang, H. Y., S. R. Reddy, and T. A. Kotchen. Antihypertensive effects of pioglitazone are not invariably associated with increased insulin sensitivity. Hypertension 24: 106-110, 1994.